# A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

> **NCT02011945** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 35 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02011945
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-07
- **Primary completion:** 2018-12-26
- **Final completion:** 2018-12-26
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02011945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02011945, "A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02011945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*